First in Man

Within the world of pharmacology, the male body has traditionally been taken as the biological norm. Coupled with this, concern about danger to the unborn foetus has meant that, until very recently, 'women of childbearing potential' were routinely excluded from most of the early phases of clinical drug testing. Consequently, most drugs tested during Phase I trials were initially carried out on healthy male volunteers. During subsequent phases when drugs were tested on patients, women remained largely under-represented. As a result, some drugs prescribed for women have later been discovered to be lacking in efficacy, and women are more likely to suffer adverse drug reactions than men. The exclusion of women during the early phases of clinical drug trials has now been lifted and drugs are currently being more widely tested on women. This paper examines the differing political and ethical positions adopted by the pharmaceutical industry, drug regulators, pharmacologists, women's groups and patient activists in relation to the exclusion and inclusion of women in clinical drug trials

Alternative medicine · Clinical research · Clinical trial · Drug · Drug trial · Inclusion (mineral) · Inclusion and exclusion criteria · Pathology · Political science · Politics · Psychiatry · Sociology · Ethics in Clinical Research · Gender Studies · Internal Medicine · Law · Medicine · Pharmaceutical industry and healthcare · Sex and Gender in Healthcare

• Feminist Bioethics

  Jackie Leach Scully•Oxford Handbook of Feminist…•2021

  Incluir item

• Gendered Logics of Biomedical Research

  Open Access•Marci D Cottingham, Jill A Fisher•Social Problems•2020

  Incluir item

• Using “Clinical Trial Diaries” to Track Patterns of Participation for Serial Healthy Volunteers in U.S. Phase I Studies

  Open Access•Heather Edelblute, Jill A Fisher•Journal of Empirical Research on…•2015

  Incluir item

• Female Tactics and Strategies of Intimate Partner Violence

  Richard E Ward, John P Muldoon•Sociological Spectrum•2007

  Incluir item

• Disadvantaged, outnumbered, and discouraged

  Open Access•Nupur Jain, Marci D Cottingham et al.•Critical Public Health•2018

  Incluir item

• Boundary setting in breast cancer research

  Open Access•Victoria Armstrong, Norma Morris•Sociology of Health & Illness•2010

  Incluir item

• Stopped hearts, amputated toes and Nasa

  Open Access•Jill A Fisher•Sociology of Health & Illness•2015

  Incluir item

• An Elusive Evidence Base

  Open Access•Ayo Wahlberg, Linsey Mcgoey•BioSocieties•2007

  Incluir item

• Risk and Emotion Among Healthy Volunteers in Clinical Trials

  Open Access•Marci D Cottingham, Jill A Fisher•Social Psychology Quarterly•2016

  Incluir item

• Challenging Assumptions About Minority Participation in US Clinical Research

  Jill A Fisher, Corey A Kalbaugh•American Journal of Public Health•2011

  Incluir item

• Feeding and Bleeding

  Open Access•Jill A Fisher•Science Technology & Human Values•2015

  Incluir item

• Equality versus Reproductive Risk

  Sara Matthiesen•Signs: Journal of Women in…•2016

  Incluir item

• Incidence of Adverse Drug Reactions in Hospitalized Patients

  Jason Lazarou, Bruce Pomeranz et al.•JAMA•1998

  Incluir item

• Activism, Drug Regulation, and the Politics of Therapeutic Evaluation in the Aids Era

  Open Access•Steven Epstein•Social Studies of Science•1997

  Incluir item

• Case Studies in Medical Ethics

  Peter Kong-Ming New, Robert M Veatch•Contemporary Sociology A Journal…•1978

  Incluir item

• A risky business

  Open Access•Owen Corrigan, Oonagh P Corrigan•Social Science & Medicine•2002

  Incluir item